Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

about

Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.

P2860

Q34975934-41371C9C-EB4A-4162-9C63-7ABEDDA4BC6A Q39321579-92303617-24AE-4FF7-B3E6-85706089BB4A

P2860

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

Item

http://www.wikidata.org/entity/Q38087371

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

@en

type

Item

label

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

@en

prefLabel

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

@en

P1476

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

@en

P2093

Jeong M Park

http://www.w3.org/2001/XMLSchema#string

Marie A Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.

Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients.

Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?

Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.

Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.

24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience.

Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.

P304

807-815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.778244

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23469871

http://www.w3.org/2001/XMLSchema#string

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

about

P2860

P2860

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698